TALS insider filings
Talaris Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-07-06. Screen TALS transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for TALS between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Talaris Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-07-06 | 4 | Requadt Scott | Tax withholding (F): 11,786 @ $3.08 | EDGAR |
| 2023-07-06 | 4 | Fenton Mary Kay — Chief Financial Officer | Tax withholding (F): 12,946 @ $3.08 | EDGAR |
| 2023-06-14 | 4 | Ildstad Suzanne — Director | Sale (S): 16,870 @ $2.59 · Sale (S): 14,208 @ $2.56 · Sale (S): 12,942 @ $2.49 · Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | Agarwala Sandip — Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | MACKAY GEOFFREY — Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | Shah Gaurav — Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | Smith Karen L. — Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | Srivastava Sapna — Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | Nader Francois — Director | Grant/award (A): 41,000 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | MCDADE MARK — Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Ildstad Suzanne — Director | Sale (S): 75,001 @ $2.39 · Sale (S): 40,642 @ $2.48 · Sale (S): 25,419 @ $2.46 | EDGAR |
| 2023-06-07 | 4 | Ildstad Suzanne — Director | Sale (S): 7,841 @ $2.52 · Sale (S): 25,549 @ $2.53 | EDGAR |
| 2023-06-05 | 4 | Ildstad Suzanne — Director | Sale (S): 15,713 @ $2.56 · Sale (S): 15,818 @ $2.50 | EDGAR |
| 2023-04-25 | 4 | Ildstad Suzanne — Director | Sale (S): 15,004 @ $2.35 | EDGAR |
| 2023-04-21 | 4 | Ildstad Suzanne — Director | Sale (S): 21,753 @ $2.16 · Sale (S): 46,990 @ $2.33 | EDGAR |
| 2023-04-19 | 4 | Ildstad Suzanne — Director | Sale (S): 99,771 @ $2.14 · Sale (S): 49,211 @ $2.15 | EDGAR |
| 2023-04-07 | 4/A | Ildstad Suzanne — Director | Sale (S): 10,436 @ $2.06 | EDGAR |
| 2023-04-07 | 4/A | Ildstad Suzanne — Director | Sale (S): 6,806 @ $2.06 | EDGAR |
| 2023-04-07 | 4/A | Ildstad Suzanne — Director | Sale (S): 29 @ $2.05 | EDGAR |
| 2023-04-07 | 4/A | Ildstad Suzanne — Director | Sale (S): 3,500 @ $2.05 | EDGAR |
| 2023-04-07 | 4/A | Ildstad Suzanne — Director | Sale (S): 2,939 @ $2.06 · Sale (S): 3,612 @ $2.05 | EDGAR |
| 2023-03-20 | 4 | Ildstad Suzanne — Director | Sale (S): 10,436 @ $2.06 | EDGAR |
| 2023-03-07 | 4 | Ildstad Suzanne — Director | Sale (S): 6,806 @ $2.06 | EDGAR |
| 2023-03-02 | 4 | Ildstad Suzanne — Director | Sale (S): 29 @ $2.05 | EDGAR |
| 2023-02-23 | 4 | Ildstad Suzanne — Director | Sale (S): 3,500 @ $2.05 | EDGAR |
| 2023-02-21 | 4 | Ildstad Suzanne — Director | Sale (S): 2,939 @ $2.06 · Sale (S): 3,612 @ $2.05 | EDGAR |
| 2023-02-03 | 4 | Zdanowski Michael — Chief Technology Officer | Grant/award (A): 150,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-02-03 | 4 | Krieger Nancy — Chief Medical Officer | Grant/award (A): 120,000 (derivative) @ $0 · Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2023-02-03 | 4 | Requadt Scott — Chief Executive Officer, Director | Grant/award (A): 4 @ $0.87 · Grant/award (A): 320,000 (derivative) @ $0 · Grant/award (A): 320,000 (derivative) @ $0 | EDGAR |
| 2023-02-03 | 4 | Fenton Mary Kay — Chief Financial Officer | Grant/award (A): 150,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2022-09-13 | 4 | Zdanowski Michael — Chief Technology Officer | Grant/award (A): 120,000 @ $0 | EDGAR |
| 2022-09-13 | 4 | Krieger Nancy — Chief Medical Officer | Grant/award (A): 80,000 @ $0 | EDGAR |
| 2022-09-13 | 4 | Requadt Scott — Chief Executive Officer, Director | Grant/award (A): 80,000 @ $0 | EDGAR |
| 2022-09-13 | 4 | Fenton Mary Kay — Chief Financial Officer | Grant/award (A): 80,000 @ $0 | EDGAR |
| 2022-09-13 | 4/A | Nader Francois — Director | Purchase (P): 50,000 @ $3.52 · Purchase (P): 52,000 @ $3.62 · Other (J): 248,432 @ $0 · Other (J): 248,432 @ $0 · Purchase (P): 36,500 @ $3.72 · Other (J): 138,500 @ $0 · +1 more | EDGAR |
| 2022-08-23 | 4 | Ildstad Suzanne — Chief Scientific Officer | Sale (S): 525,000 @ $2.80 | EDGAR |
| 2022-08-02 | 4 | Requadt Scott — Chief Executive Officer, Director | Purchase (P): 39,382 @ $4.25 | EDGAR |
| 2022-07-28 | 4 | Requadt Scott — Chief Executive Officer, Director | Purchase (P): 5,528 @ $4.24 · Purchase (P): 3,090 @ $4.25 | EDGAR |
| 2022-07-26 | 4 | Requadt Scott — Chief Executive Officer, Director | Purchase (P): 9,444 @ $3.75 | EDGAR |
| 2022-07-25 | 4 | Nader Francois — Director | Purchase (P): 50,000 @ $3.52 · Purchase (P): 52,000 @ $3.62 · Other (J): 248,432 @ $0 · Other (J): 248,432 @ $0 · Purchase (P): 36,500 @ $3.72 · Other (J): 138,500 @ $0 · +1 more | EDGAR |
| 2022-06-13 | 4 | Agarwala Sandip — Director, 10% owner | Grant/award (A): 14,501 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | MACKAY GEOFFREY — Director | Grant/award (A): 14,501 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Shah Gaurav — Director | Grant/award (A): 14,501 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Smith Karen L. — Director | Grant/award (A): 14,501 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Srivastava Sapna — Director | Grant/award (A): 14,501 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Nader Francois — Director | Grant/award (A): 14,501 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | MCDADE MARK — Director | Grant/award (A): 14,501 (derivative) @ $0 | EDGAR |
| 2022-05-17 | 4 | Smith Karen L. — Director | Grant/award (A): 29,002 (derivative) @ $0 | EDGAR |
| 2022-02-02 | 4 | Requadt Scott — Chief Executive Officer, Director | Grant/award (A): 1,470 @ $13 · Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2022-02-02 | 4 | Fenton Mary Kay — Chief Financial Officer | Grant/award (A): 1,000 @ $13 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Talaris Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-10-28 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-09-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-09 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2025-06-06 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-05-20 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events | EDGAR |
| 2025-05-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TALS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs